-
公开(公告)号：US20180354939A1
公开(公告)日：2018-12-13
申请号：US16108964
申请日：2018-08-22
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： J. Eric Carlson , Hans Hansen , Lynn Hawkins , Sally Ishizaka , Matthew Mackey , Shawn Schiller , Chikako Ogawa , Heather Davis , Atsushi Endo
IPC: C07D417/14 , C07D403/14 , C07D413/04 , C07D401/10 , C07D401/14 , C07D471/10 , C07D487/10 , C07D471/04 , C07D215/48 , C12Q1/6897 , G01N33/50 , C07D451/04 , C07D487/04 , C07D493/10 , C07D413/14
CPC classification number: C07D417/14 , C07B2200/07 , C07D215/48 , C07D401/10 , C07D401/14 , C07D403/14 , C07D413/04 , C07D413/14 , C07D451/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D493/10 , C12Q1/6897 , G01N33/5023 , G01N33/5047
Abstract: Embodiments of the disclosure relate to selectively substituted quinolone compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
-
公开(公告)号：US20140012011A1
公开(公告)日：2014-01-09
申请号：US13947593
申请日：2013-07-22
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Francis G. Fang , James E. Foy , Lynn Hawkins , Charles Lemelin , Andre LesCarbeau , Xiang Niu , Kuo-Ming Wu
IPC: C07D263/14
CPC classification number: C07D263/14 , C07C217/28 , C07C271/16 , C07F9/091 , C07F9/1411 , C07F9/2408
Abstract: The present invention provides methods for preparing TLR-4 receptor agonist E6020: and stereoisomers thereof, which compounds are useful as an immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases. Also provided are synthetic intermediates.
Abstract translation: 本发明提供了制备TLR-4受体激动剂E6020及其立体异构体的方法，当与抗原如用于细菌和病毒疾病的疫苗共同施用时，该化合物可用作免疫佐剂。 还提供了合成中间体。
-
公开(公告)号：USRE47193E1
公开(公告)日：2019-01-08
申请号：US15668887
申请日：2017-08-04
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： J. Eric Carlson , Hans Hansen , Lynn Hawkins , Sally Ishizaka , Matthew Mackey , Shawn Schiller , Chikako Ogawa , Heather Davis , Atsushi Endo
IPC: C07D413/04 , C07D401/14 , C07D403/14 , C07D401/10 , C07D413/14 , C07D417/14 , C07D215/48 , C07D471/04 , C07D471/10 , C07D487/10 , C12Q1/6897 , C07D493/10 , C07D487/04 , G01N33/50 , C07D451/04
Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
-
公开(公告)号：US09663486B2
公开(公告)日：2017-05-30
申请号：US14908164
申请日：2014-10-14
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Roch Boivin , Hans Hansen , Sally Ishizaka , Matthew Mackey , Shawn Schiller , Chikako Ogawa , Sridhar Narayan , Peter Bertinato , Gregory Berger , Atsushi Endo , Robert T. Yu , Lynn Hawkins
IPC: C07D401/02 , C07D413/14 , C07D471/04 , C07D401/14 , C07D417/14 , C07D401/04
CPC classification number: C07D401/02 , C07D401/04 , C07D401/14 , C07D413/14 , C07D417/14 , C07D471/04
Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
-
Patent Agency Ranking
公开(公告)号：US09428495B2
公开(公告)日：2016-08-30
申请号：US14513556
申请日：2014-10-14
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Eric Carlson , Hans Hansen , Lynn Hawkins , Sally Ishizaka , Matthew Mackey , Shawn Schiller , Chikako Ogawa , Heather Davis , Atsushi Endo
IPC: C07D413/04 , C07D413/14 , C07D401/10 , C07D401/14 , C07D403/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/10 , C07D215/48
CPC classification number: C07D417/14 , C07B2200/07 , C07D215/48 , C07D401/10 , C07D401/14 , C07D403/14 , C07D413/04 , C07D413/14 , C07D451/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D493/10 , C12Q1/6897 , G01N33/5023 , G01N33/5047
Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
Abstract translation: 本公开的实施方案涉及用作Toll样受体7和/或8的拮抗剂或抑制剂的选择性取代的喹啉化合物及其在有效治疗系统性红斑狼疮（SLE）和狼疮性肾炎的药物组合物中的用途。
-
公开(公告)号：US10087174B2
公开(公告)日：2018-10-02
申请号：US15670904
申请日：2017-08-07
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： J. Eric Carlson , Lynn Hawkins , Sally Ishizaka , Shawn Schiller , Chikako Ogawa , Atsushi Endo
IPC: C07D413/14 , C07D417/14 , C07D413/04 , C07D215/48 , C07D471/04 , C07D487/10 , C07D471/10 , C07D401/14 , C07D401/10 , C07D403/14 , C07D451/04 , C07D487/04 , C07D493/10 , C12Q1/6897 , G01N33/50
Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
-
公开(公告)号：US08962857B2
公开(公告)日：2015-02-24
申请号：US14269659
申请日：2014-05-05
Applicant: Eisai R&D Management Co.. Ltd.
Inventor： Francis G. Fang , James E. Foy , Lynn Hawkins , Charles Lemelin , Andre LesCarbeau , Xiang Niu , Kuo-Ming Wu
IPC: C07D263/02
CPC classification number: C07D263/14 , C07C217/28 , C07C271/16 , C07F9/091 , C07F9/1411 , C07F9/2408
Abstract: The present invention provides methods for preparing TLR-4 receptor agonist E6020: and stereoisomers thereof, which compounds are useful as an immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases. Also provided are synthetic intermediates.
Abstract translation: 本发明提供了制备TLR-4受体激动剂E6020及其立体异构体的方法，当与抗原如用于细菌和病毒疾病的疫苗共同施用时，该化合物可用作免疫佐剂。 还提供了合成中间体。
-
公开(公告)号：US20140323739A1
公开(公告)日：2014-10-30
申请号：US14269659
申请日：2014-05-05
Applicant: Eisai R&D Management Co.. Ltd.
Inventor： Francis G. Fang , James E. Foy , Lynn Hawkins , Charles Lemelin , Andre LesCarbeau , Xiang Niu , Kuo-Ming Wu
IPC: C07D263/14
CPC classification number: C07D263/14 , C07C217/28 , C07C271/16 , C07F9/091 , C07F9/1411 , C07F9/2408
Abstract: The present invention provides methods for preparing TLR-4 receptor agonist E6020: and stereoisomers thereof, which compounds are useful as an immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases. Also provided are synthetic intermediates.
-
公开(公告)号：US08754236B2
公开(公告)日：2014-06-17
申请号：US13947593
申请日：2013-07-22
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Francis G. Fang , James E. Foy , Lynn Hawkins , Charles Lemelin , Andre LesCarbeau , Xiang Niu , Kuo-Ming Wu
IPC: C07D263/08
CPC classification number: C07D263/14 , C07C217/28 , C07C271/16 , C07F9/091 , C07F9/1411 , C07F9/2408
Abstract: The present invention provides methods for preparing TLR-4 receptor agonist E6020: and stereoisomers thereof, which compounds are useful as an immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases. Also provided are synthetic intermediates.
Abstract translation: 本发明提供了制备TLR-4受体激动剂E6020及其立体异构体的方法，当与抗原如用于细菌和病毒疾病的疫苗共同施用时，该化合物可用作免疫佐剂。 还提供了合成中间体。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.026 seconds)
